Add us as your preferred source on Google to see more of our content in Search.
Add to Preferred SourcesUnitaid is investing US$ 20 million in measures to avert hundreds of thousands of preventable deaths among people with advanced HIV.
The initiative seeks to forge a more effective global response to diagnosing and treating people whose immune systems are so weakened by HIV that they are at risk of infection by other life-threatening diseases.
The grant, to be implemented by Clinton Health Access Initiative (CHAI), will help make new, WHO-recommended medicines and testing tools affordable and available in lower-income countries.
“This promises to be an enormous benefit not only to individuals but to the global HIV response,” Unitaid Executive Director Lelio Marmora said. “Addressing advanced HIV could prevent four out of ten HIV-related deaths every year.”
The intention is to create a model for tackling advanced HIV that can be scaled up by national governments and funding partners such as the Global Fund and Pepfar.
The new investment builds on Unitaid’s 2016-2019 work with CHAI to expand access to the best available antiretrovirals.
“Millions of lives have been saved by greater access to antiretroviral therapy, but many people with advanced HIV are still at risk of dying,” said Peter Sands, Executive Director of the Global Fund. “By taking on this challenge together, we can move toward our common goal of ending HIV.”
Extraordinary progress has been made over the past two decades in expanding access to treatment for HIV and encouraging people to test and begin treatment earlier. However, deaths from HIV-related diseases have not decreased as much as expected; they stand at about one million annually.
Original source: Unitaid
Published on 25 January 2019